Company Consultant Conflict Of Interest Awareness Necessary - Ganley
This article was originally published in The Tan Sheet
Executive Summary
Sponsor companies presenting data supporting approval of new OTC drugs may not always benefit from consultant comments at advisory committee meetings due to financial conflicts of interest, according to FDA Division of OTC Drug Products Director Charles Ganley, MD.